Innate Pharma (IPHA) said Monday its investigational new drug application has been cleared by the US Food and Drug Administration for a phase 1 trial of IPH4502, an antibody drug conjugate targeting Nectin-4 in solid tumors.
The trial, to start in coming months, will include dose escalation and optimization sections and will assess the safety, tolerability and preliminary efficacy of IPH4502 as a single agent, the company said.
Innate Pharma shares were more than 7% higher in premarket trading.
Price: 2.2600, Change: +0.15, Percent Change: +7.11
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。